Anika Reports Second Quarter 2026 Financial Results
Anika Therapeutics reported Q2 2026 revenue of $32.6 million, up 16% year-over-year, driven by a record $13.9 million in commercial channel revenue. Gross margin expanded to 65%, contributing to net income of $3.3 million and adjusted EBITDA of $7.1 million, the highest since 2020. Based on the strong performance, the company raised its full-year 2026 guidance for revenue growth to 5%-10% and adjusted EBITDA margin to 13%-17%.
Key figures
- Eps
- 0.24
- Revenue
- 32600000
- Guidance
- 2026 revenue growth 5%-10%, Adj EBITDA margin 13%-17%; 2027 total revenue flat to 5% growth
- Net income
- 3300000
- Oem revenue
- 18700000
- Gross profit
- 21200000
- Adjusted ebitda
- 7100000
- Commercial revenue
- 13900000
- Cash and equivalents
- 38400000
- Commercial revenue yoy
- 0.17
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.